Chronos Archive seal
The Human Record

Flannery O'Connor

Case HR-ML046 · Modern EHR teaching episode · Draft for review

Review summary

Historical dates
March 25, 1925 – August 3, 1964
Synthetic DOB
2001-03-25
Index visit
2026-04-13 at age 25
Synthetic MRN
HR-ML046-SYN

Teaching objective: Recognize systemic lupus erythematosus in a woman of 25 with inflammatory arthritis, fever, a malar rash, cytopenias, and protein and blood in the urine, rather than calling it rheumatoid arthritis; classify it with the 2019 EULAR/ACR criteria (ANA, anti-dsDNA, anti-Sm, complements, antiphospholipid antibodies) and tell her the diagnosis directly. Measure the urine protein-to-creatinine ratio, biopsy the kidney, and treat class III lupus nephritis as the 2024 ACR and 2023 EULAR guidance advise: hydroxychloroquine for every patient with baseline eye screening, pulse then tapering glucocorticoids kept to 5 mg a day or less, mycophenolate with belimumab, and an angiotensin receptor blocker. Protect bone and watch for avascular necrosis, give vaccinations before immunosuppression, protect her from the sun, manage cardiovascular risk, plan contraception and any future pregnancy with her antiphospholipid status in mind, and protect her writing life. The teaching note contrasts this with the high-dose steroid treatment, the steroid bone damage, and the concealment of her diagnosis that she lived through.

Historical timeline

DateEventClaims
March 25, 1925Born in Savannah, Georgia.CLM-0001
1937Her father's lupus diagnosed after an illness first thought to be rheumatoid arthritis.CLM-0002
1941Her father died of systemic lupus erythematosus.CLM-0002
1947Completed the Iowa Writers' Workshop.CLM-0003
December 1949Month-long hospital stay in Georgia with an operation for a floating kidney.CLM-0004
1950, by DecemberJoint pain in Connecticut, suspected to be rheumatoid arthritis; in December, admitted to hospital in Georgia and diagnosed with systemic lupus erythematosus in Atlanta.CLM-0005, CLM-0006, CLM-0012
1951Learned her diagnosis from a friend; treated with daily ACTH injections; moved to Andalusia.CLM-0007, CLM-0008, CLM-0009
1952Wise Blood published.CLM-0016
Spring 1954Limp and hip pain from bone damage attributed to steroids; crutches for most of her remaining years.CLM-0010, CLM-0011
First half of 1961Steroids tapered; chloroquine added.CLM-0013
Early 1964Surgery for a bleeding fibroid tumor reactivated her lupus; her kidneys were affected.CLM-0014
August 3, 1964Died in Milledgeville, Georgia.CLM-0015

Evidence claims

D = documented, R = retrospective, S = synthetic.

GradeClaimCertaintySources
D Mary Flannery O'Connor was born in Savannah, Georgia, on March 25, 1925, the only child of Edward Francis O'Connor and Regina Cline O'Connor. She later dropped her first name for her writing. confirmed Flannery O'Connor: biographical timeline (American Masters) supports
Flannery O'Connor (1925-1964). New Georgia Encyclopedia supports
O'Connor, Flannery. Scribner Encyclopedia of American Lives, Thematic Series: The 1960s supports
Peacocks and the Red Wolf. The Pharos of Alpha Omega Alpha, Spring 2019:27-32 supports
D Her father was diagnosed with lupus in 1937; his illness began with a whitish patch of skin on his forehead and arthritis, and was first diagnosed as rheumatoid arthritis. He died of systemic lupus erythematosus in 1941, a month after his 45th birthday, when she was 15.
The documented family history of systemic lupus erythematosus in a first-degree relative.
confirmed Peacocks and the Red Wolf. The Pharos of Alpha Omega Alpha, Spring 2019:27-32 supports
Flannery O'Connor (1925-1964). New Georgia Encyclopedia supports
Flannery O'Connor: biographical timeline (American Masters) supports
Dances with wolves. Hektoen International, Spring 2016 supports
D O'Connor graduated from Georgia State College for Women in 1945 and then studied at the Writers' Workshop of the State University of Iowa, where she earned a Master of Fine Arts; she was writing her first novel by the late 1940s. confirmed Peacocks and the Red Wolf. The Pharos of Alpha Omega Alpha, Spring 2019:27-32 supports
Flannery O'Connor: biographical timeline (American Masters) supports
D In December 1949, at 24, she fell seriously ill on a holiday visit to Georgia and spent about a month in hospital, where she had an operation for a floating kidney.
A physician friend later speculated that this was the first sign of lupus; a review in a medical society journal notes that lupus nephritis is usually painless, so whether it was is unclear.
confirmed Peacocks and the Red Wolf. The Pharos of Alpha Omega Alpha, Spring 2019:27-32 supports
Dances with wolves. Hektoen International, Spring 2016 supports
D In 1950, while living in Connecticut and writing Wise Blood, O'Connor developed joint pain; rheumatoid arthritis was suspected, a diagnosis that later proved wrong.
The documented presentation that the synthetic episode echoes; the month of onset is not given.
confirmed Peacocks and the Red Wolf. The Pharos of Alpha Omega Alpha, Spring 2019:27-32 supports
Dances with wolves. Hektoen International, Spring 2016 supports
D In December 1950 she traveled home to Georgia by train and arrived looking very ill. She was admitted to hospital in Milledgeville, kidney disease was suspected, and on the advice of an Atlanta kidney specialist who suspected lupus she was moved to Emory Hospital in Atlanta, where a positive LE cell test confirmed systemic lupus erythematosus.
Sources date the diagnosis to late 1950 or January 1951; it was made in Atlanta.
confirmed Peacocks and the Red Wolf. The Pharos of Alpha Omega Alpha, Spring 2019:27-32 supports
O'Connor, Flannery. Scribner Encyclopedia of American Lives, Thematic Series: The 1960s supports
Flannery O'Connor: biographical timeline (American Masters) supports
D Fearing the shock of her having the disease that had killed her father, her mother chose not to tell her the diagnosis; O'Connor learned that she had lupus from a friend in mid-1951.
Documented nondisclosure within the family; the synthetic episode tells her the diagnosis directly. No decision in the modern episode is attributed to any relative.
confirmed Peacocks and the Red Wolf. The Pharos of Alpha Omega Alpha, Spring 2019:27-32 supports
D She was discharged on daily injections of ACTH, which she learned to give herself, and was later treated with cortisone and prednisone. In early 1953 she wrote that she was nearly bald on top and had a "watermelon face".
Hair loss and a round face are taken by the medical authors as signs of steroid treatment (iatrogenic Cushing syndrome).
confirmed Peacocks and the Red Wolf. The Pharos of Alpha Omega Alpha, Spring 2019:27-32 supports
Dances with wolves. Hektoen International, Spring 2016 supports
O'Connor, Flannery. Scribner Encyclopedia of American Lives, Thematic Series: The 1960s supports
D From 1951 until 1964 O'Connor lived with her mother at Andalusia, the family farm outside Milledgeville, Georgia, where she wrote and kept peafowl and other birds. confirmed Flannery O'Connor (1925-1964). New Georgia Encyclopedia supports
Peacocks and the Red Wolf. The Pharos of Alpha Omega Alpha, Spring 2019:27-32 supports
O'Connor, Flannery. Scribner Encyclopedia of American Lives, Thematic Series: The 1960s supports
D By the spring of 1954 she had a limp and progressive hip pain, and she used crutches for most of her remaining years. She later wrote that her doctors had found that her "bone disintegration is being caused by the steroid drugs" she had taken for years.
Her own report of her physicians' finding, as quoted in a medical society journal.
confirmed Peacocks and the Red Wolf. The Pharos of Alpha Omega Alpha, Spring 2019:27-32 supports
O'Connor, Flannery. Scribner Encyclopedia of American Lives, Thematic Series: The 1960s supports
R Physician authors attribute her hip disease to avascular necrosis of the femoral head from steroid treatment, and suggest that her jaw may have been affected in the same way.
Retrospective medical interpretation from her letters and photographs; no imaging from her lifetime was reviewed.
probable Peacocks and the Red Wolf. The Pharos of Alpha Omega Alpha, Spring 2019:27-32 supports
R Physician authors suggest from her letters and photographs that she may have had a malar facial rash early in her illness and the hand deformities of Jaccoud arthropathy.
Retrospective interpretation; not used as a historical finding.
possible Peacocks and the Red Wolf. The Pharos of Alpha Omega Alpha, Spring 2019:27-32 supports
D Her steroid treatment was tapered in the first half of 1961, when she was also taking chloroquine.
Later than the synthetic episode and not used in it.
confirmed Peacocks and the Red Wolf. The Pharos of Alpha Omega Alpha, Spring 2019:27-32 supports
D In early 1964 she was anemic from a bleeding fibroid tumor and had abdominal surgery to remove it; the tumor was benign, but the operation reactivated her lupus, which had been in remission, and her kidneys were affected.
One source describes the operation as a hysterectomy. Later than the synthetic episode and not used in it.
confirmed Flannery O'Connor (1925-1964). New Georgia Encyclopedia supports
O'Connor, Flannery. Scribner Encyclopedia of American Lives, Thematic Series: The 1960s supports
Peacocks and the Red Wolf. The Pharos of Alpha Omega Alpha, Spring 2019:27-32 supports
Flannery O'Connor: biographical timeline (American Masters) supports
D Her novel Wise Blood was published in 1952 and A Good Man Is Hard to Find and Other Stories in 1955; The Complete Stories won the National Book Award after her death. confirmed Peacocks and the Red Wolf. The Pharos of Alpha Omega Alpha, Spring 2019:27-32 supports
Flannery O'Connor: biographical timeline (American Masters) supports
D O'Connor died of kidney failure from lupus in the Baldwin County Hospital in Milledgeville on August 3, 1964, at 39.
Record the death as a fact without detail.
confirmed Flannery O'Connor (1925-1964). New Georgia Encyclopedia supports
O'Connor, Flannery. Scribner Encyclopedia of American Lives, Thematic Series: The 1960s supports
Flannery O'Connor: biographical timeline (American Masters) supports
Peacocks and the Red Wolf. The Pharos of Alpha Omega Alpha, Spring 2019:27-32 supports

Modern synthetic problem list

GradeProblemClinical statusVerificationPlacementHistorical claims
S Pain and swelling of the small joints of both hands, the wrists, and the knees for three months, with an hour of morning stiffness, evening fevers to 38 °C, fatigue, and a red rash over the cheeks and nose after sun; told elsewhere it might be rheumatoid arthritis; cause to be established resolved confirmed active CLM-0005
S Protein and blood in the urine: protein-to-creatinine ratio 1.6 g/g and 18 red cells per high-power field, with normal creatinine; cause to be established resolved confirmed active
S Systemic lupus erythematosus, classified by the EULAR/ACR criteria (ANA 1:640 homogeneous; score 32 before the biopsy): inflammatory arthritis, acute cutaneous lupus (malar rash), fever, leukopenia with lymphopenia, mild thrombocytopenia, low C3 and C4, anti-dsDNA and anti-Sm positive; antiphospholipid antibodies and lupus anticoagulant negative active confirmed both_with_link CLM-0006, CLM-0002
S Lupus nephritis, ISN/RPS class III (A), focal proliferative, on kidney biopsy: endocapillary proliferation in 9 of 30 glomeruli, activity index 6 of 24, chronicity index 1 of 12, full-house immunofluorescence; no thrombotic microangiopathy; urine protein-to-creatinine ratio 1.8 g/g; normal kidney function active confirmed active CLM-0006, CLM-0015
S Long-term glucocorticoid treatment for lupus nephritis, tapering to 5 mg a day or less active confirmed active CLM-0008, CLM-0010
S Long-term mycophenolate mofetil, with belimumab, for lupus nephritis; bone and infection protection in place active confirmed active
S Levonorgestrel intrauterine system for highly effective contraception during mycophenolate treatment active confirmed active
S Acute cystitis on mycophenolate, belimumab, and prednisone 15 mg: two days of burning, frequency, and urgency without fever or flank pain; urine culture grew Escherichia coli sensitive to nitrofurantoin; resolved with seven days of nitrofurantoin resolved confirmed active

Synthetic outcome measures

GradeDateMeasureResultCoding
S 2026-04-13 Hemoglobin [Mass/volume] in Blood 11 g/dL (low)
Reference 12-15.5 g/dL
http://loinc.org · 718-7
S 2026-04-13 Leukocytes [#/volume] in Blood by Automated count 3.3 10*3/uL (low)
Reference 4-11 10*3/uL
http://loinc.org · 6690-2
S 2026-04-13 Lymphocytes [#/volume] in Blood by Automated count 0.8 10*3/uL (low)
Reference 1-4.8 10*3/uL
http://loinc.org · 731-0
S 2026-04-13 Platelets [#/volume] in Blood by Automated count 138 10*3/uL (low)
Reference 150-400 10*3/uL
http://loinc.org · 777-3
S 2026-04-13 Creatinine [Mass/volume] in Serum or Plasma 0.8 mg/dL
Reference 0.5-1.1 mg/dL
http://loinc.org · 2160-0
S 2026-04-13 Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M 101 mL/min/1.73 m²
Reference >=60 mL/min/1.73 m²
http://loinc.org · 98979-8
S 2026-04-13 Potassium [Moles/volume] in Serum or Plasma 4.2 mmol/L
Reference 3.5-5.1 mmol/L
http://loinc.org · 2823-3
S 2026-04-13 Albumin [Mass/volume] in Serum or Plasma 3.3 g/dL (low)
Reference 3.5-5 g/dL
http://loinc.org · 1751-7
S 2026-04-13 Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma 19 U/L
Reference <=33 U/L
http://loinc.org · 1742-6
S 2026-04-13 Erythrocyte [Sedimentation Rate] in Blood by Westergren method 52 mm/h (high)
Reference <=20 mm/h
http://loinc.org · 4537-7
S 2026-04-13 C reactive protein [Mass/volume] in Serum or Plasma 0.6 mg/dL (high)
Reference <=0.5 mg/dL
http://loinc.org · 1988-5
S 2026-04-13 Protein/Creatinine [Mass Ratio] in Urine 1.6 g/g (high)
Reference <=0.2 g/g
http://loinc.org · 2890-2
S 2026-04-13 Erythrocytes [#/area] in Urine sediment by Microscopy high power field 18 /[HPF] (high)
Reference <=2 /[HPF]
http://loinc.org · 13945-1
S 2026-04-13 Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] 7 http://loinc.org · 44261-6
S 2026-04-13 Pain severity - 0-10 verbal numeric rating [Score] - Reported 6 http://loinc.org · 72514-3
S 2026-04-22 Nuclear Ab [Titer] in Serum by Immunofluorescence 640 (high)
Reference Negative at 1:40 or less; the EULAR/ACR entry criterion is 1:80 or higher
http://loinc.org · 5048-4
S 2026-04-22 DNA double strand Ab [Units/volume] in Serum 186 [IU]/mL (high)
Reference <=29 [IU]/mL
http://loinc.org · 5130-0
S 2026-04-22 Smith extractable nuclear Ab [Units/volume] in Serum 42 U/mL (high)
Reference <=19 U/mL
http://loinc.org · 11090-8
S 2026-04-22 Complement C3 [Mass/volume] in Serum or Plasma 62 mg/dL (low)
Reference 90-180 mg/dL
http://loinc.org · 4485-9
S 2026-04-22 Complement C4 [Mass/volume] in Serum or Plasma 8 mg/dL (low)
Reference 10-40 mg/dL
http://loinc.org · 4498-2
S 2026-04-22 Cardiolipin IgG Ab [Units/volume] in Serum by Immunoassay 6 U/mL
Reference <=20 U/mL
http://loinc.org · 3181-5
S 2026-04-22 Cardiolipin IgM Ab [Units/volume] in Serum by Immunoassay 4 U/mL
Reference <=20 U/mL
http://loinc.org · 3182-3
S 2026-04-22 Beta 2 glycoprotein 1 IgG Ab [Units/volume] in Serum 3 U/mL
Reference <=20 U/mL
http://loinc.org · 16135-6
S 2026-04-22 Beta 2 glycoprotein 1 IgM Ab [Units/volume] in Serum 2 U/mL
Reference <=20 U/mL
http://loinc.org · 16136-4
S 2026-04-22 dRVVT/dRVVT W excess phospholipid (screen to confirm ratio) 1.04
Reference <=1.2
http://loinc.org · 50410-0
S 2026-04-22 Protein/Creatinine [Mass Ratio] in Urine 1.8 g/g (high)
Reference <=0.2 g/g
http://loinc.org · 2890-2
S 2026-04-22 Erythrocytes [#/area] in Urine sediment by Microscopy high power field 22 /[HPF] (high)
Reference <=2 /[HPF]
http://loinc.org · 13945-1
S 2026-04-22 Creatinine [Mass/volume] in Serum or Plasma 0.8 mg/dL
Reference 0.5-1.1 mg/dL
http://loinc.org · 2160-0
S 2026-04-22 Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M 101 mL/min/1.73 m²
Reference >=60 mL/min/1.73 m²
http://loinc.org · 98979-8
S 2026-04-29 Hemoglobin [Mass/volume] in Blood 11.2 g/dL (low)
Reference 12-15.5 g/dL
http://loinc.org · 718-7
S 2026-04-29 Leukocytes [#/volume] in Blood by Automated count 3.6 10*3/uL (low)
Reference 4-11 10*3/uL
http://loinc.org · 6690-2
S 2026-04-29 Lymphocytes [#/volume] in Blood by Automated count 0.9 10*3/uL (low)
Reference 1-4.8 10*3/uL
http://loinc.org · 731-0
S 2026-04-29 Platelets [#/volume] in Blood by Automated count 151 10*3/uL
Reference 150-400 10*3/uL
http://loinc.org · 777-3
S 2026-04-29 Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma 18 U/L
Reference <=33 U/L
http://loinc.org · 1742-6
S 2026-04-29 25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma 26 ng/mL (low)
Reference 30-100 ng/mL
http://loinc.org · 62292-8
S 2026-04-29 DXA Lumbar spine [Z-score] Bone density -0.4
Reference Z-score above -2.0 is within the expected range for age
http://loinc.org · 85394-5
S 2026-04-29 DXA Femur [Z-score] Bone density -0.2
Reference Z-score above -2.0 is within the expected range for age
http://loinc.org · 80934-3
S 2026-07-27 Hemoglobin [Mass/volume] in Blood 12.1 g/dL
Reference 12-15.5 g/dL
http://loinc.org · 718-7
S 2026-07-27 Leukocytes [#/volume] in Blood by Automated count 5.2 10*3/uL
Reference 4-11 10*3/uL
http://loinc.org · 6690-2
S 2026-07-27 Lymphocytes [#/volume] in Blood by Automated count 1 10*3/uL
Reference 1-4.8 10*3/uL
http://loinc.org · 731-0
S 2026-07-27 Platelets [#/volume] in Blood by Automated count 212 10*3/uL
Reference 150-400 10*3/uL
http://loinc.org · 777-3
S 2026-07-27 Creatinine [Mass/volume] in Serum or Plasma 0.8 mg/dL
Reference 0.5-1.1 mg/dL
http://loinc.org · 2160-0
S 2026-07-27 Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M 101 mL/min/1.73 m²
Reference >=60 mL/min/1.73 m²
http://loinc.org · 98979-8
S 2026-07-27 Potassium [Moles/volume] in Serum or Plasma 4.4 mmol/L
Reference 3.5-5.1 mmol/L
http://loinc.org · 2823-3
S 2026-07-27 Albumin [Mass/volume] in Serum or Plasma 3.8 g/dL
Reference 3.5-5 g/dL
http://loinc.org · 1751-7
S 2026-07-27 Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma 22 U/L
Reference <=33 U/L
http://loinc.org · 1742-6
S 2026-07-27 Protein/Creatinine [Mass Ratio] in Urine 0.9 g/g (high)
Reference <=0.2 g/g
http://loinc.org · 2890-2
S 2026-07-27 Erythrocytes [#/area] in Urine sediment by Microscopy high power field 6 /[HPF] (high)
Reference <=2 /[HPF]
http://loinc.org · 13945-1
S 2026-07-27 DNA double strand Ab [Units/volume] in Serum 72 [IU]/mL (high)
Reference <=29 [IU]/mL
http://loinc.org · 5130-0
S 2026-07-27 Complement C3 [Mass/volume] in Serum or Plasma 84 mg/dL (low)
Reference 90-180 mg/dL
http://loinc.org · 4485-9
S 2026-07-27 Complement C4 [Mass/volume] in Serum or Plasma 13 mg/dL
Reference 10-40 mg/dL
http://loinc.org · 4498-2
S 2026-07-27 25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma 36 ng/mL
Reference 30-100 ng/mL
http://loinc.org · 62292-8
S 2026-07-27 Cholesterol [Mass/volume] in Serum or Plasma 212 mg/dL (high)
Reference <=199 mg/dL
http://loinc.org · 2093-3
S 2026-07-27 Cholesterol in HDL [Mass/volume] in Serum or Plasma 58 mg/dL
Reference >=50 mg/dL
http://loinc.org · 2085-9
S 2026-07-27 Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation 128 mg/dL (high)
Reference <=99 mg/dL
http://loinc.org · 13457-7
S 2026-07-27 Triglyceride [Mass/volume] in Serum or Plasma 130 mg/dL
Reference <=149 mg/dL
http://loinc.org · 2571-8
S 2026-07-27 Hemoglobin A1c/Hemoglobin.total in Blood 5.3%
Reference <=5.6%
http://loinc.org · 4548-4
S 2026-07-27 Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] 4 http://loinc.org · 44261-6
S 2026-07-27 Pain severity - 0-10 verbal numeric rating [Score] - Reported 1 http://loinc.org · 72514-3
S 2026-10-26 Hemoglobin [Mass/volume] in Blood 12.8 g/dL
Reference 12-15.5 g/dL
http://loinc.org · 718-7
S 2026-10-26 Leukocytes [#/volume] in Blood by Automated count 5.6 10*3/uL
Reference 4-11 10*3/uL
http://loinc.org · 6690-2
S 2026-10-26 Lymphocytes [#/volume] in Blood by Automated count 1.2 10*3/uL
Reference 1-4.8 10*3/uL
http://loinc.org · 731-0
S 2026-10-26 Platelets [#/volume] in Blood by Automated count 236 10*3/uL
Reference 150-400 10*3/uL
http://loinc.org · 777-3
S 2026-10-26 Creatinine [Mass/volume] in Serum or Plasma 0.8 mg/dL
Reference 0.5-1.1 mg/dL
http://loinc.org · 2160-0
S 2026-10-26 Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M 101 mL/min/1.73 m²
Reference >=60 mL/min/1.73 m²
http://loinc.org · 98979-8
S 2026-10-26 Potassium [Moles/volume] in Serum or Plasma 4.3 mmol/L
Reference 3.5-5.1 mmol/L
http://loinc.org · 2823-3
S 2026-10-26 Albumin [Mass/volume] in Serum or Plasma 4.1 g/dL
Reference 3.5-5 g/dL
http://loinc.org · 1751-7
S 2026-10-26 Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma 20 U/L
Reference <=33 U/L
http://loinc.org · 1742-6
S 2026-10-26 Protein/Creatinine [Mass Ratio] in Urine 0.35 g/g (high)
Reference <=0.2 g/g
http://loinc.org · 2890-2
S 2026-10-26 Erythrocytes [#/area] in Urine sediment by Microscopy high power field 2 /[HPF]
Reference <=2 /[HPF]
http://loinc.org · 13945-1
S 2026-10-26 DNA double strand Ab [Units/volume] in Serum 38 [IU]/mL (high)
Reference <=29 [IU]/mL
http://loinc.org · 5130-0
S 2026-10-26 Complement C3 [Mass/volume] in Serum or Plasma 96 mg/dL
Reference 90-180 mg/dL
http://loinc.org · 4485-9
S 2026-10-26 Complement C4 [Mass/volume] in Serum or Plasma 18 mg/dL
Reference 10-40 mg/dL
http://loinc.org · 4498-2
S 2026-10-26 Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] 3 http://loinc.org · 44261-6
S 2026-10-26 Pain severity - 0-10 verbal numeric rating [Score] - Reported 0 http://loinc.org · 72514-3
S 2026-06-15 Leukocytes [#/volume] in Blood by Automated count 7.9 10*3/uL
Reference 4-11 10*3/uL
http://loinc.org · 6690-2
S 2026-06-15 Creatinine [Mass/volume] in Serum or Plasma 0.8 mg/dL
Reference 0.5-1.1 mg/dL
http://loinc.org · 2160-0
S 2026-06-15 Potassium [Moles/volume] in Serum or Plasma 4.6 mmol/L
Reference 3.5-5.1 mmol/L
http://loinc.org · 2823-3
S 2026-10-05 Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] 0 http://loinc.org · 55758-7
S 2026-10-05 Total score [AUDIT-C] 1 http://loinc.org · 75626-2

Synthetic vital signs

DateMeasureResultLOINCGrade
2026-04-13Body height168 cm8302-2S
2026-04-13Body weight60 kg29463-7S
2026-04-13Body mass index (BMI) [Ratio]21.3 kg/m239156-5S
2026-04-13Systolic blood pressure138 mm[Hg]8480-6S
2026-04-13Diastolic blood pressure86 mm[Hg]8462-4S
2026-04-13Heart rate96 /min8867-4S
2026-04-13Respiratory rate16 /min9279-1S
2026-04-13Body temperature37.9 Cel8310-5S
2026-04-13Oxygen saturation in Arterial blood by Pulse oximetry98 %59408-5S
2026-04-22Body height168 cm8302-2S
2026-04-22Body weight59.6 kg29463-7S
2026-04-22Body mass index (BMI) [Ratio]21.1 kg/m239156-5S
2026-04-22Systolic blood pressure136 mm[Hg]8480-6S
2026-04-22Diastolic blood pressure84 mm[Hg]8462-4S
2026-04-22Heart rate92 /min8867-4S
2026-04-22Respiratory rate16 /min9279-1S
2026-04-22Body temperature37.6 Cel8310-5S
2026-04-22Oxygen saturation in Arterial blood by Pulse oximetry98 %59408-5S
2026-04-29Body height168 cm8302-2S
2026-04-29Body weight59.8 kg29463-7S
2026-04-29Body mass index (BMI) [Ratio]21.2 kg/m239156-5S
2026-04-29Systolic blood pressure128 mm[Hg]8480-6S
2026-04-29Diastolic blood pressure80 mm[Hg]8462-4S
2026-04-29Heart rate84 /min8867-4S
2026-04-29Respiratory rate14 /min9279-1S
2026-04-29Body temperature37 Cel8310-5S
2026-04-29Oxygen saturation in Arterial blood by Pulse oximetry99 %59408-5S
2026-07-27Body height168 cm8302-2S
2026-07-27Body weight63.4 kg29463-7S
2026-07-27Body mass index (BMI) [Ratio]22.5 kg/m239156-5S
2026-07-27Systolic blood pressure122 mm[Hg]8480-6S
2026-07-27Diastolic blood pressure78 mm[Hg]8462-4S
2026-07-27Heart rate76 /min8867-4S
2026-07-27Respiratory rate14 /min9279-1S
2026-07-27Body temperature36.7 Cel8310-5S
2026-07-27Oxygen saturation in Arterial blood by Pulse oximetry99 %59408-5S
2026-10-26Body height168 cm8302-2S
2026-10-26Body weight62 kg29463-7S
2026-10-26Body mass index (BMI) [Ratio]22 kg/m239156-5S
2026-10-26Systolic blood pressure118 mm[Hg]8480-6S
2026-10-26Diastolic blood pressure76 mm[Hg]8462-4S
2026-10-26Heart rate72 /min8867-4S
2026-10-26Respiratory rate14 /min9279-1S
2026-10-26Body temperature36.6 Cel8310-5S
2026-10-26Oxygen saturation in Arterial blood by Pulse oximetry99 %59408-5S
2026-06-15Body height168 cm8302-2S
2026-06-15Body weight62.4 kg29463-7S
2026-06-15Body mass index (BMI) [Ratio]22.1 kg/m239156-5S
2026-06-15Systolic blood pressure124 mm[Hg]8480-6S
2026-06-15Diastolic blood pressure78 mm[Hg]8462-4S
2026-06-15Heart rate84 /min8867-4S
2026-06-15Respiratory rate14 /min9279-1S
2026-06-15Body temperature37.3 Cel8310-5S
2026-06-15Oxygen saturation in Arterial blood by Pulse oximetry99 %59408-5S
2026-10-05Body height168 cm8302-2S
2026-10-05Body weight62.2 kg29463-7S
2026-10-05Body mass index (BMI) [Ratio]22 kg/m239156-5S
2026-10-05Systolic blood pressure116 mm[Hg]8480-6S
2026-10-05Diastolic blood pressure74 mm[Hg]8462-4S
2026-10-05Heart rate70 /min8867-4S
2026-10-05Respiratory rate14 /min9279-1S
2026-10-05Body temperature36.6 Cel8310-5S
2026-10-05Oxygen saturation in Arterial blood by Pulse oximetry99 %59408-5S

Social, functional, and mental status

Social history

Functional status

Mental status

Allergies and medications

Allergies

Medications

Procedures and immunizations

Procedures

Immunizations

Past medical history

True biography with historical dates; not part of the synthetic care timeline.

Family history

Care-plan goals

GoalTarget dateStatusOutcome
Establish the diagnosis within two weeks and hear it directly, in plain words2026-04-22completedTold directly at nine days that she has systemic lupus erythematosus, with the reasons and a written summary
Renal response: urine protein-to-creatinine ratio halved by three months and below 0.5 g/g with stable kidney function by six to twelve months2026-10-26completedRatio 1.8 at diagnosis, 0.9 at three months, 0.35 at six months, a complete response; creatinine 0.8 throughout
Prednisone 5 mg a day or less by six months, with withdrawal considered later2026-10-26completed5 mg a day at six months
Write at least four mornings a week through treatment2026-12-31activeWriting five mornings a week by three months
No unplanned pregnancy on mycophenolate; plan any pregnancy for a time of quiet disease on compatible medicines2026-12-31activeIntrauterine system in place; pregnancy planning discussed

Interventions

InterventionStatusGuideline
Inflammatory arthritis with fever, rash, cytopenias, and an abnormal urine: blood count, chemistry, ESR and CRP, urine microscopy and protein-to-creatinine ratio today; ANA, anti-dsDNA, anti-Sm, complements, and antiphospholipid antibodies; no NSAIDs with protein in the urinecompletedGL-EULAR-ACR-CRIT-2019, GL-ACR-LN-2024
Rheumatology consultation within ten days, to confirm the diagnosis, stage organ involvement, and plan treatment with hercompletedGL-EULAR-SLE-2023
Disclosure: every result explained to her directly and in plain words, with a written copy; her health shared only with the people she namescompletedGL-EULAR-SLE-2023
Sun protection: broad-spectrum sunscreen SPF 50 or higher, a wide-brimmed hat, and shade in the middle of the daycompletedGL-EULAR-SLE-2023
Hydroxychloroquine 300 mg daily (5 mg/kg) for every patient with lupus, long term, with a baseline eye examination within the first year and yearly screening after five yearscompletedGL-EULAR-SLE-2023, GL-AAO-HCQ-2016
Kidney biopsy for proteinuria above 0.5 g/g with an active sediment, to class the nephritis before treatmentcompletedGL-ACR-LN-2024
Vaccinations before immunosuppression: PCV20 and recombinant zoster dose 1 now, zoster dose 2 after one to two months, seasonal influenza and COVID-19; no live vaccines on immunosuppression; hepatitis B, hepatitis C, and HIV screeningcompletedGL-ACR-VAX-2022, GL-CDC-IMZ-MC-2026
Angiotensin receptor blocker (losartan) for proteinuria and blood pressure, target below 130/80 mmHg, with potassium and creatinine two to four weeks after startingcompletedGL-ACR-LN-2024, GL-CMID-2026
Contraception before mycophenolate: highly effective method of her choice (levonorgestrel intrauterine system); pregnancy test before starting; pregnancy planning later for at least six months of quiet disease on pregnancy-compatible medicinescompletedGL-ACR-REPRO-2020, GL-FDA-MMF-2026
Class III lupus nephritis: methylprednisolone 500 mg daily for three days, then prednisone 30 mg tapered to 5 mg a day or less by six months; mycophenolate mofetil 2 g a day with belimumab, continued for three to five years after a complete response; blood counts weekly for the first month, twice monthly for the next two, then monthly; urine protein-to-creatinine ratio, urine sediment, creatinine, anti-dsDNA, and complements every three monthscompletedGL-ACR-LN-2024, GL-EULAR-SLE-2023, GL-FDA-MMF-2026, GL-FDA-BELIMUMAB-2026
Bone protection on glucocorticoids: baseline DXA, vitamin D3 and calcium from food, weight-bearing exercise; report new hip, groin, or knee pain at once so avascular necrosis can be looked for with MRIcompletedGL-ACR-GIOP-2022, GL-EULAR-SLE-2023
Cardiovascular risk: blood pressure at every visit, lipids and HbA1c at three months on glucocorticoids, no smoking, activity, and a lower glucocorticoid dosecompletedGL-EULAR-SLE-2023
Writing life: treatment visits and infusions booked in the afternoons, belimumab self-injected at home, fatigue managed with graded activity and sleep; her illness kept out of conversations about her work unless she chooses otherwisecompletedGL-EULAR-SLE-2023

Planned encounters

Supporting documents

C-CDA note documents

Each link opens a readable copy; the XML beside it is the exchange file.

Sources

IDSourcePublisherType
SRC-0001 Peacocks and the Red Wolf. The Pharos of Alpha Omega Alpha, Spring 2019:27-32 Alpha Omega Alpha Honor Medical Society scholarly
SRC-0002 Flannery O'Connor: biographical timeline (American Masters) PBS (WNET) biography
SRC-0003 Flannery O'Connor (1925-1964). New Georgia Encyclopedia Georgia Humanities and the University of Georgia Press biography
SRC-0004 O'Connor, Flannery. Scribner Encyclopedia of American Lives, Thematic Series: The 1960s Encyclopedia.com (Scribner) biography
SRC-0005 Dances with wolves. Hektoen International, Spring 2016 Hektoen Institute of Medicine other
SRC-0006 Lupus in the mid-20th century: the life and death of Flannery O'Connor. J Clin Rheumatol 2011;17(5):266-268. PMID 21778907 Journal of Clinical Rheumatology (PubMed record) scholarly
SRC-0007 Flannery O'Connor's lupus. A commentary on her collected letters, The Habit of Being. JAMA 1980;244(13):1441-1442. PMID 6999184 JAMA (PubMed record) scholarly
SRC-0008 HISTMED Master Roster v3 The Human Record project other

Review status

ReviewStatusNotes
schema validationnot_startedRun scripts/build.ps1 -Conformance.
clinical reviewnot_startedAwaiting clinician review; check the EULAR/ACR scoring, the indication for kidney biopsy and the class III result, the choice of mycophenolate with belimumab over a calcineurin inhibitor, the glucocorticoid taper, the contraception choice, and the bone and vaccination plans.
provenance reviewnot_startedHer lupus, her father's lupus, the ACTH and later steroid treatment, the hip disease and crutches, the 1964 surgery, and her death are documented from a medical society journal article drawing on her letters and the standard biography, PBS, the New Georgia Encyclopedia, a Scribner reference biography, and a medical humanities essay. Avascular necrosis and an early malar rash are physicians' retrospective interpretations (R). Her mother appears only in a documented claim; no relative is quoted or makes any decision.
safe messaging reviewnot_startedNo behavioral-health diagnosis; mild depressive symptoms at diagnosis are screened and improve; the concealment of her diagnosis within her family is recorded factually without judgment; death recorded without detail.

Comments and corrections

Sign in with GitHub to comment on this record. To report a specific error, ideally with a source, use the feedback form; each report becomes a tracked issue.

Comments appear on the online version of this page.